Immutep Announces Publication Of Abstracts For ASCO 2023 Annual Meeting
Portfolio Pulse from Happy Mohamed
Immutep Limited has published data from Part C of its TACTI-002 Phase II trial, showing promising results for eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma. The treatment was safe and well-tolerated, with a 29.7% response rate and a 12-month overall survival rate of 46.0%.
May 26, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep's TACTI-002 Phase II trial data shows promising results for eftilagimod alpha plus pembrolizumab in metastatic head and neck cancer, potentially boosting the company's stock.
The positive results from Immutep's TACTI-002 Phase II trial indicate that the company's eftilagimod alpha plus pembrolizumab treatment is effective in treating metastatic head and neck cancer. This could lead to increased interest in the company's stock, as investors may see potential for growth in the cancer treatment market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100